- Report
- July 2020
- 213 Pages
China
From €3073EUR$3,200USD£2,646GBP
- Report
- April 2020
- 108 Pages
Global
From €1153EUR$1,200USD£992GBP
- Report
- February 2022
- 135 Pages
Global
From €2392EUR$2,490USD£2,059GBP
- Report
- January 2020
United States
From €1335EUR$1,390USD£1,149GBP
- Report
- May 2022
- 110 Pages
Global
From €4274EUR$4,450USD£3,680GBP
- Report
- October 2023
- 74 Pages
Global
From €3500EUR$3,904USD£3,119GBP
The Pneumonia Vaccine market is a subset of the larger Vaccines market. It is composed of vaccines that protect against the bacteria and viruses that cause pneumonia. These vaccines are typically administered to infants, children, and adults, and are recommended by the World Health Organization (WHO). The market is highly competitive, with a number of companies offering different types of vaccines.
The Pneumonia Vaccine market is driven by the increasing prevalence of the disease, as well as the need for improved immunization coverage. Additionally, the development of new technologies and the introduction of new vaccines have also contributed to the growth of the market.
Some of the major companies in the Pneumonia Vaccine market include Merck & Co., GlaxoSmithKline, Pfizer, Sanofi, and AstraZeneca. These companies are involved in the development, manufacturing, and distribution of various types of pneumonia vaccines. Show Less Read more
